Verax Biomedical
Marlborough, US · 1 known investors
Verax Biomedical develops PGDprime, a bacterial detection system for blood platelet screening that meets FDA guidance on bacterial risk control. The product is designed for blood collection establishments to enhance pathogen detection while enabling extended product shelf life.
Founders & leadership
JR
JOE R. SANDERSExecutive
YR
YLI REMO VALLEJOExecutive
RS
R. SCOTT MCKENZIE, SR.Executive
NA
NANCY A. HORNBAKERExecutive
PR
PAUL RAGUSAExecutive
Board
MG
MARC GOLDBERGBoard director
JL
JAMES LOUSARARIANBoard director
JD
JOE DEL GUERCIOBoard director
JK
JAMES KOZIARZBoard director
RZ
ROBERT ZIESERLBoard director
BB
BUZZ BENSONBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$30.6M disclosed across 4 rounds · 2015–2019
▶$2.5MraisedSep 2019 · 5 investors · BiotechnologyRule 506(b)
▶$2.5MraisedSep 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James LousararianExecutive Officer, Director
- Paul RagusaExecutive Officer
- Joe SandersDirector
- Robert FlanaganDirector
- Marc GoldbergDirector
- Offering amount
- $10.5M
- Amount sold
- $2.5M
- Sales commissions
- $425K
- Placement agents
- Thomas Frederick Zipser
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.4MraisedNov 2017 · 4 investors · BiotechnologyRule 506(b)
▶$11.4MraisedNov 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES LOUSARARIANExecutive Officer, Director
- JOE SANDERSExecutive Officer, Director
- MARC E. GOLDBERGDirector
- JOE DEL GUERCIODirector
- Offering amount
- $24.1M
- Amount sold
- $11.4M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.6MraisedJun 2016 · 64 investors · BiotechnologyRule 506(b)
▶$12.6MraisedJun 2016 · 64 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- PAUL RAGUSAExecutive Officer
- MARC E. GOLDBERGDirector
- JAMES KOZIARZDirector
- JAMES LOUSARARIANExecutive Officer, Director
- YLI REMO VALLEJOExecutive Officer
- JOE DEL GUERCIODirector
- NANCY A. HORNBAKERExecutive Officer
- JOE R. SANDERSExecutive Officer, Director
- R. SCOTT MCKENZIEExecutive Officer
- Offering amount
- $24.5M
- Amount sold
- $12.6M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedJan 2015 · 61 investors · BiotechnologyRule 506(b)
▶$4MraisedJan 2015 · 61 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JAMES KOZIARZDirector
- JOE R. SANDERSExecutive Officer, Director
- ROBERT ZIESERLDirector
- BUZZ BENSONDirector
- YLI REMO VALLEJOExecutive Officer
- R. SCOTT MCKENZIE, SR.Executive Officer
- NANCY A. HORNBAKERExecutive Officer
- PAUL RAGUSAExecutive Officer
- MARC GOLDBERGDirector
- JAMES LOUSARARIANExecutive Officer, Director
- JOE DEL GUERCIODirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Verax Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Verax Biomedical do?
- Verax Biomedical develops PGDprime, a bacterial detection system for blood platelet screening that meets FDA guidance on bacterial risk control. The product is designed for blood collection establishments to enhance pathogen detection while enabling extended product shelf life.
- Who are Verax Biomedical's investors?
- Verax Biomedical's investors include Bioventures Investors.
- How much funding has Verax Biomedical raised?
- Verax Biomedical has disclosed $30.6M raised across 4 rounds.
- Where is Verax Biomedical headquartered?
- Verax Biomedical is headquartered in Marlborough, US.